Tissue reaction & tumor response with negative pi mesons. 1980

M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson

As a prelude to a randomized trial of negative pi meson (pion) radiotherapy, as compared to conventional radiation treatment, tolerance of several normal tissues was investigated. Fifty-three of 108 patients received at least 2700 peak pion rads at a usual dose rate between 100 and 125 rads daily. The major sites treated were head and neck, pancreas, prostate, rectum and brain. Acute normal tissue reactions, late effects, and tumor response are correlated with the two dose levels. Pancreatic tumors have not fared well. At this point, tumors that can be observed disappear more rapidly, and, for tumors that cannot be observed, symptoms disappear more rapidly and normal tissues exhibit less reaction than with conventional radiotherapy. It is believed that the dose level can be raised an additional 7 percent above the current 4100 rads, measured at the maximum within the treatment volume.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011830 Radiation Effects The effects of ionizing and nonionizing radiation upon living organisms, organs and tissues, and their constituents, and upon physiologic processes. It includes the effect of irradiation on food, drugs, and chemicals. Effects, Radiation,Effect, Radiation,Radiation Effect
D011836 Radiation Tolerance The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS. Radiation Sensitivity,Radiosensitivity,Sensitivity, Radiation,Tolerance, Radiation,Radiation Sensitivities,Radiation Tolerances,Radiosensitivities,Sensitivities, Radiation,Tolerances, Radiation

Related Publications

M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
November 1978, Rinsho hoshasen. Clinical radiography,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
July 1973, Radiology,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
July 1981, International journal of radiation oncology, biology, physics,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
October 1977, Strahlentherapie,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
January 1979, International journal of radiation oncology, biology, physics,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
February 1976, Radiology,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
February 1976, The British journal of radiology,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
February 1975, Meditsinskaia radiologiia,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
July 1981, The British journal of radiology,
M M Kligerman, and J M Sala, and A R Smith, and E A Knapp, and H Tsujii, and M A Bagshaw, and S Wilson
March 1978, Radiology,
Copied contents to your clipboard!